Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

351P - The application of peripheral blood immune profiling in personalized treatment of advanced lung cancer: A nomogram approach

Date

28 Mar 2025

Session

Poster Display session

Presenters

Chuanwang Miao

Citation

Journal of Thoracic Oncology (2025) 20 (3): S208-S232. 10.1016/S1556-0864(25)00632-X

Authors

C. Miao1, T. Yin2

Author affiliations

  • 1 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy, Jinan/CN
  • 2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN

Resources

This content is available to ESMO members and event participants.

Abstract 351P

Background

As a pivotal way to reactivate immune cells, immunotherapy has been a powerful way for tumor control in lung cancer patients. Peripheral blood lymphocyte subsets, accessible through noninvasive liquid biopsy, have the accessibility to predict immunotherapy outcomes and optimize patient selection.

Methods

We enrolled 171 patients with lung cancer who underwent chemotherapy with or without immunotherapy. Peripheral blood lymphocyte profiles at different timepoints were examined to identify associations with treatment response from different treatment regimens, survival outcomes, and relevant clinical factors, aiming to determine their predictive value for post-treatment outcomes.

Results

Elevated baseline levels of CD3–CD16+CD56+ and CD3–CD19+ cells, along with a higher CD4+/CD8+ T cell ratio, were positively correlated with favorable treatment responses, particularly in patients receiving chemotherapy combined with immunotherapy. Conversely, increased CD3+ and CD3+CD8+ T cell counts were linked to lower response rates. A nomogram incorporating five immune parameters achieved an AUC of 0.778 in the entire cohort, out-performing each individual marker. In the subset receiving combination therapy, a fourparameter model yielded an AUC of 0.725, again surpassing the predictive accuracy of single indicators. Dynamic assessments suggested limited changes in these subsets at disease progression, highlighting their utility for early-stage prediction rather than late-treatment guidance.

Conclusions

Baseline and early-treatment peripheral blood lymphocyte subsets offer a promising, noninvasive strategy for predicting therapeutic efficacy in locally advanced or advanced lung cancer. Furthermore, utilizing a multifaceted predictive framework that incorporates various lymphocyte subset parameters provides a more dependable forecast of treatment outcomes, thereby aiding in tailored patient selection for immunotherapy.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.